NZ515541A - Pharmaceutical compositions comprising bisphosphonates to treat angiogenesis - Google Patents

Pharmaceutical compositions comprising bisphosphonates to treat angiogenesis

Info

Publication number
NZ515541A
NZ515541A NZ515541A NZ51554100A NZ515541A NZ 515541 A NZ515541 A NZ 515541A NZ 515541 A NZ515541 A NZ 515541A NZ 51554100 A NZ51554100 A NZ 51554100A NZ 515541 A NZ515541 A NZ 515541A
Authority
NZ
New Zealand
Prior art keywords
bisphosphonates
patient
pharmaceutical compositions
treatment
treat angiogenesis
Prior art date
Application number
NZ515541A
Other languages
English (en)
Inventor
Tetsuji Okuno
Jonathan Green
Jeanettemarjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ515541(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9911926.5A external-priority patent/GB9911926D0/en
Priority claimed from GBGB9925131.6A external-priority patent/GB9925131D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ515541A publication Critical patent/NZ515541A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ515541A 1999-05-21 2000-05-19 Pharmaceutical compositions comprising bisphosphonates to treat angiogenesis NZ515541A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9911926.5A GB9911926D0 (en) 1999-05-21 1999-05-21 Organic compounds
GBGB9925131.6A GB9925131D0 (en) 1999-10-22 1999-10-22 Organic compounds
PCT/EP2000/004562 WO2000071104A2 (en) 1999-05-21 2000-05-19 Use of bisphosphonic acids for treating angiogenesis

Publications (1)

Publication Number Publication Date
NZ515541A true NZ515541A (en) 2003-03-28

Family

ID=26315578

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515541A NZ515541A (en) 1999-05-21 2000-05-19 Pharmaceutical compositions comprising bisphosphonates to treat angiogenesis

Country Status (21)

Country Link
US (2) US20020142996A1 (https=)
EP (1) EP1178810B8 (https=)
JP (1) JP2003500352A (https=)
KR (1) KR100763064B1 (https=)
CN (1) CN1202828C (https=)
AT (1) ATE293450T1 (https=)
AU (1) AU775079B2 (https=)
BR (1) BR0010808A (https=)
CA (1) CA2374049A1 (https=)
DE (1) DE60019580T2 (https=)
DK (1) DK1178810T3 (https=)
ES (1) ES2240106T3 (https=)
HU (1) HUP0201329A3 (https=)
IL (2) IL146520A0 (https=)
NO (1) NO322212B1 (https=)
NZ (1) NZ515541A (https=)
PL (1) PL351674A1 (https=)
PT (1) PT1178810E (https=)
SK (1) SK16682001A3 (https=)
TW (1) TWI224504B (https=)
WO (1) WO2000071104A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1591122B1 (en) * 2000-06-20 2012-09-26 Novartis AG Method of administering bisphosphonates
CA2410201C (en) 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
EP1365769B1 (en) * 2001-02-06 2011-01-26 The Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children) A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
EP1418897A2 (en) * 2001-05-02 2004-05-19 Novartis AG Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
ES2336312T3 (es) * 2001-07-16 2010-04-12 Universite Paris 13 Procedimiento de preparacion de derivados de bisfosfonatos.
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
RU2387451C2 (ru) 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
EP1426052B1 (en) * 2002-12-02 2009-09-02 Innate Pharma Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof
CA2532948A1 (en) * 2003-07-21 2005-02-17 Novartis Ag Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
SK50782006A3 (sk) † 2004-02-26 2007-03-01 Zentiva, A. S. Amorfné formy risedronátu monosodného
EP1930011B1 (en) * 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium
US7914810B2 (en) * 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
EP2255199A1 (en) * 2008-02-19 2010-12-01 Jovesis Inc. Microparticle compositions to modify cancer promoting cells
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (en) * 2009-07-31 2017-06-06 Thar Pharma, Llc Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2015018659A1 (en) * 2013-08-05 2015-02-12 Vib Vzw Glutamine synthetase inhibitors for inhibition of pathological angiogenesis
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
DE3425812A1 (de) * 1984-07-13 1986-01-16 Deutsches Krebsforschungszentrum, 6900 Heidelberg Neue 1-hydroxy-1,1-diphosphonsaeureverbindungen, verfahren zu ihrer herstellung und pharmakologische zubereitungen, insbesondere zur behandlung von knochentumoren
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
SE9402001D0 (sv) * 1994-06-09 1994-06-09 Leiras Oy Pyridylbisphosphonates for use as a therapeutical agent
IT1290444B1 (it) * 1997-03-27 1998-12-03 Boehringer Mannheim Italia Coniugati di bis-fosfonati con funzionalita' alchilanti aventi attivita' antitumorale
TR200000145T2 (tr) * 1997-07-22 2000-05-22 Merck & Co. Inc. Kemik erimesini durdurmak için bir yöntem
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
EP0998934A4 (en) * 1997-12-25 2005-09-14 Toray Industries REMEDIES AGAINST INTRAMEDULLARY DISEASES
US6416964B2 (en) * 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
AU760703B2 (en) * 1998-01-29 2003-05-22 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance

Also Published As

Publication number Publication date
EP1178810B1 (en) 2005-04-20
DE60019580D1 (de) 2005-05-25
EP1178810A2 (en) 2002-02-13
US20040176327A1 (en) 2004-09-09
DE60019580T2 (de) 2006-03-09
EP1178810B8 (en) 2005-07-27
PL351674A1 (en) 2003-05-19
NO20015638L (no) 2002-01-15
CN1202828C (zh) 2005-05-25
KR20010113830A (ko) 2001-12-28
HUP0201329A3 (en) 2005-02-28
AU5214100A (en) 2000-12-12
US20020142996A1 (en) 2002-10-03
CA2374049A1 (en) 2000-11-30
SK16682001A3 (sk) 2002-04-04
AU775079B2 (en) 2004-07-15
DK1178810T3 (da) 2005-07-11
NO322212B1 (no) 2006-08-28
TWI224504B (en) 2004-12-01
IL146520A (en) 2006-09-05
WO2000071104A2 (en) 2000-11-30
ES2240106T3 (es) 2005-10-16
HUP0201329A2 (en) 2002-08-28
JP2003500352A (ja) 2003-01-07
ATE293450T1 (de) 2005-05-15
IL146520A0 (en) 2002-07-25
WO2000071104A3 (en) 2001-07-19
PT1178810E (pt) 2005-08-31
KR100763064B1 (ko) 2007-10-04
CN1384749A (zh) 2002-12-11
BR0010808A (pt) 2002-08-27
NO20015638D0 (no) 2001-11-19

Similar Documents

Publication Publication Date Title
NZ515541A (en) Pharmaceutical compositions comprising bisphosphonates to treat angiogenesis
Endo et al. Underlying mechanisms and therapeutic strategies for bisphosphonate-related osteonecrosis of the jaw (BRONJ)
IL155363A0 (en) Use of bisphosphonates for pain treatment
TW200744673A (en) Improved ibandronate formulations
MY141584A (en) Pharmaceutical uses of bisphosphonates
IL139229A0 (en) Drug delivery system comprising a tightly compacted solid medicament stock
FI964315A0 (fi) Bisfosfonihappojen märkärakeistusformulointi
Saad Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone
CA2409930A1 (en) Use of zoledronate for the manufacture of a medicament for the treatment of bone metabolism diseases
CN1327844C (zh) 包含双膦酸类化合物和hmg－coa还原酶抑制剂的组合疗法
TH51552A (th) การใช้กรดบิสฟอสโฟนิคสำหรับการบำบัดแอนจิโอจีนีซิส
HK1080734B (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)